{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regimen+1%2C+Course+2&page=2", "query": { "intervention": "Regimen 1, Course 2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regimen+1%2C+Course+2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T04:49:26.896Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01436305", "title": "Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Basiliximab", "type": "BIOLOGICAL" }, { "name": "Short-term Tac", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2011-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 3, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436305" }, { "nct_id": "NCT05446402", "title": "Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acne" ], "interventions": [ { "name": "Geologie Acne Regimen - one side of face", "type": "COMBINATION_PRODUCT" }, { "name": "Proactive Acne Regimen - other side of face", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2022-06-15", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05446402" }, { "nct_id": "NCT04747912", "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia", "ph+ Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Purinethol (6-Mercaptopurine)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-03-02", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747912" }, { "nct_id": "NCT00016367", "title": "Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "1999-05-13", "completion_date": "2004-12-14", "has_results": false, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016367" }, { "nct_id": "NCT00536341", "title": "Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2008-01", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2017-01-16", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 6, "location_summary": "Fort Myers, Florida • Orlando, Florida • Bethesda, Maryland + 2 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536341" }, { "nct_id": "NCT01920932", "title": "Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage II Childhood Hodgkin Lymphoma", "Stage III Childhood Hodgkin Lymphoma", "Stage IV Childhood Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Dacarbazine(R)", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "quality of life assessment", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 77, "start_date": "2013-08-12", "completion_date": "2028-05", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 6, "location_summary": "Palo Alto, California • Peoria, Illinois • Scarborough, Maine + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920932" }, { "nct_id": "NCT03920137", "title": "Adaptation and Initial Evaluation of Transdiagnostic CBT for Anxious and Depressed Smokers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "UP-ST Therapy", "type": "BEHAVIORAL" }, { "name": "Standard Therapy", "type": "BEHAVIORAL" }, { "name": "Nicotine Patch", "type": "DEVICE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE" ], "sponsor": "University of Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 70, "start_date": "2020-12-20", "completion_date": "2024-02", "has_results": false, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03920137" }, { "nct_id": "NCT03483337", "title": "New MRI Biomarkers in Head and Neck Cancers", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer", "Thyroid Cancer" ], "interventions": [ { "name": "MRI examinations", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2018-03-16", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03483337" }, { "nct_id": "NCT04178005", "title": "Cladribine Tablets After Treatment With Natalizumab (CLADRINA)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2020-02-19", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 2, "location_summary": "Overland Park, Kansas • Dallas, Texas", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04178005" }, { "nct_id": "NCT04039217", "title": "Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ART", "HIV" ], "interventions": [ { "name": "Biktarvy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 20, "start_date": "2019-09-30", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-09-25T04:49:26.896Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039217" } ] }